Baker Bros. Advisors LP Altimmune, Inc. Transaction History

Baker Bros. Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $9.75 Million - $18.4 Million	-1,116,119 Reduced 63.07%	653,562 $10.8 Million
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $3.26 Million - $6.85 Million	-305,722 Reduced 14.73%	1,769,681 $22.6 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $3.95 Million - $11.8 Million	1,003,365 Added 93.59%	2,075,403 $24.3 Million
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $16.6 Million - $27.8 Million	-1,686,480 Reduced 61.14%	1,072,038 $10.6 Million
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $11.1 Million - $21.2 Million	874,067 Added 46.38%	2,758,518 $39 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $2.53 Million - $4.59 Million	-322,504 Reduced 14.61%	1,884,451 $21.3 Million
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $986,595 - $3.3 Million	99,355 Added 4.71%	2,206,955 $29.1 Million
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $6.11 Million - $22.6 Million	2,107,600 New	2,107,600 $22.6 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.